Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › UBT251 phase 2 T2D China (NCT07163624)

UBT251 phase 2 T2D China (NCT07163624)

UBT251 · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
UBT251
Population
t2d
Phase
2
Participants
211
Duration
24 weeks
Registry
NCT07163624

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
4.0 mg (initial dose 0.5 mg) vs semaglutide 1 mg: weight -4.8 %, HbA1c -1.77t2d china24211——−2.0 vs −0.7——————congress
4.0 mg (initial dose 1.0 mg) vs semaglutide 1 mg: weight -4.8 %, HbA1c -1.77t2d china24211——−2.1 vs −0.7——————congress

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (2)
  • 4.0 mg (initial dose 0.5 mg) · hba1c · abstract
    change in HbA1c was -2.16% (0.122), -1.98% (0.169), -2.08% (0.170) and -2.08% (0.118) with
  • 4.0 mg (initial dose 1.0 mg) · hba1c · abstract
    change in HbA1c was -2.16% (0.122), -1.98% (0.169), -2.08% (0.170) and -2.08% (0.118) with

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: UBT251 phase 2 T2D China (NCT07163624). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-t2d-china/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.